20028-40-4

Usage

InChI:InChI=1/C9H11N3/c1-12-8-5-3-2-4-7(8)11-9(12)6-10/h2-5H,6,10H2,1H3/p+1

Upstream product

• 1442637-90-2 C₁₅H₂₁N₆⁽¹⁺⁾*Cl^(1-) 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 53332-79-9 2-aminomethyl-1-methylbenzimidazole dihydrochloride 
• 95-54-5 1,2-diamino-benzene 
• 4760-35-4 2-chloromethyl-1-methyl-1H-benzimidazole 
• 459-73-4 GlyOEt*HCl 

Downstream Products

• 440098-94-2 2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(1-methyl-1H-benzoimidazol-2-ylmethyl)-2-phenyl-acetamide 
• 949304-63-6 (2-hydroxyphenyl)[5-(1-methyl-1H-benzimidazol-2-yl)-1H-pyrrol-3-yl]methanone 
• 1612183-60-4 6-(2,3-dimethylphenyl)-4-N-[(1-methyl-1H-1,3-benzodiazol-2-yl)methyl]pyrimidine-2,4-diamine 
• 1442637-86-6 bis(2,4-dimethylphenylthiomethyl)-(1-methylbenzimidazol-2-ylmethyl)amine 
• 1422360-66-4 C₂₀H₂₀N₆O₂ 

Relevant academic research and scientific papers

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 (Ki = 0.16 μM and 0.12 μM, respectively).

CHEMICAL COMPOUNDS AS ANTIBIOTICS

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p? q, L, ?, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.

Copper versus thioether-centered oxidation: Mechanistic insights into the non-innocent redox behavior of tripodal benzimidazolylaminothioether ligands

A series of Cu+ complexes with ligands that feature varying numbers of benzimidazole/thioether donors and methylene or ethylene linkers between the central nitrogen atom and the thioether sulfur atoms have been spectroscopically and electrochemically characterized. Cyclic voltammetry measurements indicated that the highest Cu2+/Cu+ redox potentials correspond to sulfur-rich coordination environments, with values decreasing as the thioether donors are replaced by nitrogen-donating benzimidazoles. Both Cu2+ and Cu+ complexes were studied by DFT. Their electronic properties were determined by analyzing their frontier orbitals, relative energies, and the contributions to the orbitals involved in redox processes, which revealed that the HOMOs of the more sulfur-rich copper complexes, particularly those with methylene linkers (-N-CH2-S-), show significant aromatic thioether character. Thus, the theoretically predicted initial oxidation at the sulfur atom of the methylene-bridged ligands agrees with the experimentally determined oxidation waves in the voltammograms of the NS3- and N2S2-type ligands as being ligand-based, as opposed to the copper-based processes of the ethylene-bridged Cu+ complexes. The electrochemical and theoretical results are consistent with our previously reported mechanistic proposal for Cu 2+-promoted oxidative C-S bond cleavage, which in this work resulted in the isolation and complete characterization (including by X-ray crystallography) of the decomposition products of two ligands employed, further supporting the novel reactivity pathway invoked. The combined results raise the possibility that the reactions of copper-thioether complexes in chemical and biochemical systems occur with redox participation of the sulfur atom. Copyright

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Benzimidazole compounds that are vitronectin receptor antagonists

The present invention provides compounds having the formula wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d

CONVERSIONS OF 2-α-CHLOROALKYLBENZIMIDAZOLES

Upon interaction with caustic in a DMSO medium, 2-chloromethylbenzimidazoles are subjected to cyclodimerization, forming 5H,12H-pyrazinobis-benzimidazoles; in the presence of nucleophiles (ammonia, amines, anions of β-diketones), under the indicated conditions, the products are the corresponding substituted amines or derivatives of pyrrolobenzimidazole.